Cablivi

Sanofi’s Cablivi receives EC approval to treat rare blood disorder

The European Commission (EC) has granted marketing authorisation for Sanofi’s Cablivi (caplacizumab) indicated to treat adults with acquired thrombotic thrombocytopenic…